Great! We'll call you.

×

×

Send an email to sales

×

Great! We'll call you.

×

×

Send an email to sales

×

Great! We'll call you.

×

×

Send an email to sales

×

Great! We'll call you.

×

×

Send an email to sales

×

 QUBIS Innovation   Fund 

Turning high-quality academic inspiration into cutting-edge commercial innovation.

At a glance
  • Current status:                     Closed (June-21)
  • Fund type:                                              SEIS/EIS
  • Investment goal:                     Capital growth
  • Focus:  University spin-outs 

The Fund presents the opportunity for alumni and qualifying investors to make an impact investment in spin-out companies formed to commercialise scientific and technological advances made at Queen’s University Belfast. To support the Fund’s pipeline, consideration will also be given to Queen’s student ventures and spin-outs from partner Universities participating in the Queen’s administered NxNW ICURe Programme. The NxNW consortium encompasses Ulster University, University of Edinburgh, University of Liverpool, University of Sheffield, University of Manchester, and the University of Leeds.

Investment Strategy
The objective of the QUBIS Innovation Fund is to invest in a portfolio of early-stage high-growth companies from Queen’s University and other UK-based universities in the North by North West (“NxNW”) ICURe programme. These early-stage companies from leading UK universities often address problems at the heart of society. Such companies will often have a national and international economic impact. 
 
SEIS & EIS tax incentives
The companies the fund invest in are expected to be SEIS-EIS-qualifying, which makes the QUBIS Innovation Fund SEIS-EIS suitable for qualifying clients who would potentially benefit from the following tax reliefs:
  • Up to 30% income tax relief (or 50% for SEIS)
  • Tax-free investment growth
  • Capital gains deferral (50% capital gains tax exemption for SEIS)
  • Inheritance tax relief
  • Loss relief
Please note: SEIS-EIS tax reliefs are only made available to investors because of the higher risks associated with investing in early-stage companies. Also, the availability of tax reliefs will depend on the investor's individual circumstances, and may be subject to change in the future. In addition, the availability of any tax relief depends on the investee companies maintaining their qualifying status. See guide for further information.
Fund team

QUBIS portfolio companies

Liopa

Liopa spun out of Queen’s University Belfast in 2016. The company is onward developing and commercialising research carried out within the university into Visual Speech Recognition (VSR), effectively automated lip reading.

Fusion antibodies

Fusion Antibodies is dedicated to the discovery and early development of antibodies to help bring about a positive change in the healthcare industry.

CV6

CV6 Therapeutics is dedicated to the development of novel innovative therapeutics to improve the lives of patients with cancer and inflammatory diseases.

Next Slide
prev
next
Explore other investments
Important information
To invest, you must be an eligible investor. To be an eligible investor, you must be qualifying as one or more of the following:
  • You meet the FCA’s definition of a professional investor (as per COBS 3.5).
  • You meet the FCA’s definition of a certified high net worth investor (as per COBS 4 Annex 2R).
• You meet the FCA’s definition of a certified sophisticated investor (as per COBS 4 Annex 3R).
  • You meet the FCA’s definition of a self-certified sophisticated investor (as per COBS 4 Annex 4R).
  • You meet the FCA’s definition of a certified restricted investor (as per COBS 4 Annex 5R).
  • You are a client of an FCA authorised firm that will provide advice on the suitability of the product in question.
 
Risk warning
THIS INVESTMENT IS NOT SUITABLE FOR ALL INVESTORS AS THE UNDERLYING INVESTMENTS ARE ILLIQUID. 
 
This financial promotion has been approved by Sapphire Capital Partners LLP (FRN: 565716) on 01 May 2023. 
 
Important information for private investors – Reliance on the information provided here to engage in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested. Your attention is drawn to the risk section contained within the Information Memorandum. Investments are typically in unquoted shares in small companies, the value of which can be volatile and are often difficult to sell. Nothing on this website constitutes investment, tax, financial, legal, regulatory, or other advice by Sapphire Capital Partners LLP.
The value of an investment may go down as well as up, and you may not get back the full amount invested, and you may therefore lose some or all of your investment.
If you are unsure of the suitability of any investment for your circumstances, please contact your independent financial advisor or other professional advisor authorised under the Financial Services and Markets Act 2000 (FSMA) who specialises in advising on investments of this type. Tax reliefs depend on individual circumstances. There is no guarantee however that the tax reliefs (such as SEIS and/or EIS reliefs, CGT reliefs or IHT relief) will be available on any investment made or that if it is initially available, it will not be subsequently withdrawn. Any references to tax laws or rates are based on current legislation, all of which are subject to change and are provided as a guide only. Prospective investors are advised to obtain their own investment and taxation advice and should consult their own professional advisors on the implications of investing.
Investments made in investee companies via funds managed by Sapphire Capital Partners LLP may not be covered by the Financial Services Compensation Scheme (FSCS). For more details, please contact us or refer to their website: https://www.fscs.org.uk
Past performance is not a guide to future returns. CAPITAL AT RISK. 

Get in touch

We are here to help you get started.